Peter Vasas1, Waleed Al-Khyatt2, Iskandar Idris2,3, Paul C Leeder2, Altaf K Awan2, Sherif Awad4,5, Javed Ahmed2,6. 1. Doncaster Royal Infirmary, Armthorpe Road, Doncaster, DN2 5LT, UK. 2. The East-Midlands Bariatric & Metabolic Institute (EMBMI), Royal Derby Hospital, Derby Teaching Hospitals NHS Foundation Trust, Uttoxeter Road, Derby, DE22 3NE, UK. 3. School of Medicine, University of Nottingham, Derby, DE22 3DT, UK. 4. The East-Midlands Bariatric & Metabolic Institute (EMBMI), Royal Derby Hospital, Derby Teaching Hospitals NHS Foundation Trust, Uttoxeter Road, Derby, DE22 3NE, UK. sherif.awad@nhs.net. 5. School of Medicine, University of Nottingham, Derby, DE22 3DT, UK. sherif.awad@nhs.net. 6. Digestive Disease Institute, Cleveland Clinic, Abu Dhabi, United Arab Emirates.
Abstract
BACKGROUND: Laparoscopic Roux en-Y gastric bypass (LRYGB) is an established therapeutic modality for type 2 diabetes mellitus (T2DM). However, there is paucity of data on the outcomes of LRYGB on T2DM beyond 2 years. This study aimed to examine the medium-term effects of LRYGB on T2DM and determine the predictors of T2DM resolution. METHODS: Prospective data were collected for all consecutive LRYGB performed from September 2009 to November 2010. The American Diabetes Association guidelines were used to define complete (CR) or partial (PR) remission of diabetes. Diabetes status was considered improved when there was >50 % reduction in the dose of medications or when glycaemic control was achieved after stopping insulin. The effects of baseline characteristics, diabetes data and weight loss data at 4 years on T2DM remission were studied. RESULTS: Forty-six patients with T2DM underwent LRYGB with mean ± SD age and body mass index (BMI) of 48.6 ± 9.6 years and 50.4 ± 6.5 kg/m2, respectively. Median (IQR, interquartile range) duration of T2DM preoperatively was 60 (36-126) months. Median (IQR) follow-up was 52 (50-57) months. T2DM remission was achieved in 64 % of patients (44 % CR, 20 % PR), and a further 28 % of patients had improvement in their diabetes status. Multivariate analyses demonstrated significant excess weight loss (EWL) [P = 0.008] and lower BMI [P = 0.04] at 4 years to be the only independent predictors of T2DM medium-term outcomes. CONCLUSION: The medium-term effects of LRYGB on T2DM remission/improvement were maintained in 92 % of patients. EWL and lower BMI at 4 years were independent predictors of T2DM remission.
BACKGROUND: Laparoscopic Roux en-Y gastric bypass (LRYGB) is an established therapeutic modality for type 2 diabetes mellitus (T2DM). However, there is paucity of data on the outcomes of LRYGB on T2DM beyond 2 years. This study aimed to examine the medium-term effects of LRYGB on T2DM and determine the predictors of T2DM resolution. METHODS: Prospective data were collected for all consecutive LRYGB performed from September 2009 to November 2010. The American Diabetes Association guidelines were used to define complete (CR) or partial (PR) remission of diabetes. Diabetes status was considered improved when there was >50 % reduction in the dose of medications or when glycaemic control was achieved after stopping insulin. The effects of baseline characteristics, diabetes data and weight loss data at 4 years on T2DM remission were studied. RESULTS: Forty-six patients with T2DM underwent LRYGB with mean ± SD age and body mass index (BMI) of 48.6 ± 9.6 years and 50.4 ± 6.5 kg/m2, respectively. Median (IQR, interquartile range) duration of T2DM preoperatively was 60 (36-126) months. Median (IQR) follow-up was 52 (50-57) months. T2DM remission was achieved in 64 % of patients (44 % CR, 20 % PR), and a further 28 % of patients had improvement in their diabetes status. Multivariate analyses demonstrated significant excess weight loss (EWL) [P = 0.008] and lower BMI [P = 0.04] at 4 years to be the only independent predictors of T2DM medium-term outcomes. CONCLUSION: The medium-term effects of LRYGB on T2DM remission/improvement were maintained in 92 % of patients. EWL and lower BMI at 4 years were independent predictors of T2DM remission.
Authors: Lars Sjöström; Anna-Karin Lindroos; Markku Peltonen; Jarl Torgerson; Claude Bouchard; Björn Carlsson; Sven Dahlgren; Bo Larsson; Kristina Narbro; Carl David Sjöström; Marianne Sullivan; Hans Wedel Journal: N Engl J Med Date: 2004-12-23 Impact factor: 91.245
Authors: N B Jørgensen; S H Jacobsen; C Dirksen; K N Bojsen-Møller; L Naver; L Hvolris; T R Clausen; B S Wulff; D Worm; D Lindqvist Hansen; S Madsbad; J J Holst Journal: Am J Physiol Endocrinol Metab Date: 2012-04-24 Impact factor: 4.310
Authors: Philip R Schauer; Deepak L Bhatt; John P Kirwan; Kathy Wolski; Stacy A Brethauer; Sankar D Navaneethan; Ali Aminian; Claire E Pothier; Esther S H Kim; Steven E Nissen; Sangeeta R Kashyap Journal: N Engl J Med Date: 2014-03-31 Impact factor: 91.245
Authors: S R Kashyap; S Daud; K R Kelly; A Gastaldelli; H Win; S Brethauer; J P Kirwan; P R Schauer Journal: Int J Obes (Lond) Date: 2009-12-22 Impact factor: 5.095
Authors: John B Buse; Sonia Caprio; William T Cefalu; Antonio Ceriello; Stefano Del Prato; Silvio E Inzucchi; Sue McLaughlin; Gordon L Phillips; R Paul Robertson; Francesco Rubino; Richard Kahn; M Sue Kirkman Journal: Diabetes Care Date: 2009-11 Impact factor: 19.112
Authors: Sayeed Ikramuddin; Judith Korner; Wei-Jei Lee; John E Connett; William B Inabnet; Charles J Billington; Avis J Thomas; Daniel B Leslie; Keong Chong; Robert W Jeffery; Leaque Ahmed; Adrian Vella; Lee-Ming Chuang; Marc Bessler; Michael G Sarr; James M Swain; Patricia Laqua; Michael D Jensen; John P Bantle Journal: JAMA Date: 2013-06-05 Impact factor: 56.272
Authors: D J Pournaras; E T Aasheim; T T Søvik; R Andrews; D Mahon; R Welbourn; T Olbers; C W le Roux Journal: Br J Surg Date: 2011-10-21 Impact factor: 6.939
Authors: Carlos Marin; Georgios Papantonakis; Kathleen Sels; G Harry van Lenthe; Guillaume Falgayrac; Roman Vangoitsenhoven; Bart Van der Schueren; Guillaume Penel; Frank Luyten; Katleen Vandamme; Greet Kerckhofs Journal: Sci Rep Date: 2018-04-12 Impact factor: 4.379
Authors: Nicolas Colsoul; Carlos Marin; Katrien Corbeels; Greet Kerckhofs; Bart Van der Schueren; Katleen Vandamme Journal: Calcif Tissue Int Date: 2020-08-01 Impact factor: 4.333